PACE CII: What They Show and How They Can Support Policy-Reform Discussions
Policy Reforms to Speed Continuous Innovation Against Cancer
Continuous Innovation against Cancer: It's Real, It’s Valuable — but It’s Too Slow
Scoring Progress Against Cancer: The Launch of the PACE Continuous Innovation Indicators™
Value-Based Cancer Care at the ACCC National Oncology Conference
Topic: integrating the concept of value into decisions about cancer care and treatment.
Cancer Perception Index: A Global Public Opinion Poll
The PACE Cancer Perceptions Index polled over 4,300 people in six countries to find out what they think about cancer.
Our vision is simple: faster steps forward towards cures for cancer and access to best treatment and care for individual patients.
Patients Define the Value in Cancer Care
Defining value in cancer care is complex, but one thing is clear: our definition must center on patient needs and priorities.
In Cancer Care, Where do Cost and Innovation Meet?
What are the factors driving health care costs today? In the field of medicine, cost, access, and innovation are inextricably linked.
How does the cancer community define value?
Every group measures value differently, and while each definition is valid, no single definition tells the whole story.
Tackling the Complexities of Cancer Research
Dr. Richard Gaynor explains what makes the science of creating treatments for cancer so complicated, and why patients need to understand continuous innovation.
Accelerating Cancer Innovation Through Clinical Trials
Clinical trials enable doctors and scientists identify what potential medicines help patients fight their disease, and discover the safest and most effective ways to treat the different types of cancer.
PACE Clinical Trial Review
A recent multinational study explores the disconnect between clinical trial enrollment and the value clinical trials provide.
Pathway of a New Cancer Medicine
In this infographic, we take a look at the complex and lengthy process of developing a medicine to treat cancer
5 Things You Should Know About the Value of Cancer Treatments
Conversations about the value of cancer medicines often focus on cost, but a dollar figure isn't the only factor to consider when weighing a medicine's value.
eMEET (Medicine Evaluation Educational Training) is an online interactive training program designed to help patient advocates navigate through the complex world of medicine development, evaluation and assessment.
Solving the HTA Puzzle
National health agencies use a process called Health Technology Assessment (HTA) to determine whether or not to make a new medicine available to patients.
HTA experts Karen Facey, Kenneth Paterson, and Kathy Oliver introduce the eMEET interactive training program.
eMEET: A Resource
eMEET is a training resource for patient advocacy groups and anyone interested in gaining an overview of medicines development, evaluation and assessment.
MEET puts patients at the heart of medicine development, evaluation and assessment.